Jump to content

User:Fu Hung Shiu/sandbox

From Wikipedia, the free encyclopedia
Thota Ganesh
Born (1970-05-10) May 10, 1970 (age 54)
Celina, Ohio, U.S.
Education
Occupations
  • Pharmacologist
  • neurobiologist
Known forGlutamate receptor biology; neuroinflammation
Medical career
FieldNeuroscience, Neurology
InstitutionsEmory University School of Medicine

Thota Ganesh(born May 10, 1970) is an Indian-American scientist who has made considerable contributions to the field of organic chemistry and Medicinal chemistry. He serves as associate professor in the School of Medicine at Emory University, Atlanta GA.

Education

[edit]

Ganesh grew up in Anantasagar, a village in Telangana, India. He attended obtained Bachler degree in Osmania University, and also got his Master's degree (1994) and Ph.D (1999) in organic chemistry at the same institute. He obtained postdoc training at IIT-Bombay, Durham University (UK), and Virginia Tech (USA) before moving to Emory University (USA)

Career

[edit]

Ganesh is an associate professor in the Department of Pharmacology at Emory University. He served in several national and international scientific committees including National Institutes of Health (NIH) grant review committees and served on the scientific review board of ADDF. He co-founded (along with Raymond J. Dingledine and Dennis McNamara) a small pharma company called Pyrefin Inc., in 2019, which develops novel anti-inflammatory drugs to treat memory and cognitive deficits in Epilepsy and other neurodgenerative diseases such as Alzheimer’s disease. He serves on board of Pyrefin, Inc

Research and work

[edit]

His early research focused on the modulation of glutamate receptor-mediated synaptic transmission.[1] During this period he and his team discovered that glycine is a coagonist rather than modulator of NMDA receptors,[2] that shrinkage of extracellular space mediates the transition between interictal and ictal states in the high potassium model of seizures,[3][4] that a single amino acid residue controls calcium permeation in glutamate receptor channels,[5] and that ifenprodil analogs inhibit NMDA receptors by increasing the sensitivity of receptors to proton inhibition.[6] His current research focuses on the myriad roles of neuroinflammation in neurologic disorders.[7] He demonstrated a profound role for EP2 receptor activation by prostaglandin E2 in COX-2 related pathologies.[8] His work highlights the importance of neuroinflammation in epilepsy.

Awards and honors

[edit]

Dingledine was elected to the US National Academy of Medicine in 2010,[9] the Norwegian Academy of Science and Letters in 2018,[10] and the National Academy of Inventors in 2022.[11] He was elected as a Fellow of American Association for Advancement of Science in 2003, and a Fellow of the American Society for Pharmacology and Experimental Therapeutics in 2020.[12] His early career was profiled in Nature Medicine in 2002.[13] He received the Bristol-Myers Squibb Neuroscience Award in 1989 and again in 1993, the epilepsy basic research award from the American Epilepsy Society in 1995, a Javits Neuroscience Award from the National Institute of Neurological Disorders and Stroke in 1998, the PhRMA Foundation Career Award in Excellence in 1999, and the Robert R Ruffolo Career Achievement Award from the American Society of Pharmacology and Experimental Therapeutics in 2018.[14] Two endowed prizes have been established in his name, the Ray Dingledine Award for Extraordinary Graduate Achievement in 2018[15] and the Ray Dingledine Research Impact Award in Pharmacology & Chemical Biology (2019).[16] In 2023, he is awarded the inaugural AMSPC Award in Pharmacology Research and Administration from the Association of Medical School Pharmacology Chairs (AMSPC).

Personal life

[edit]

Dingledine has two sons, Brian and Roger. Dingledine has grown bonsai trees since 1971 and for many years was an avid swimmer with a local Master’s group. He competed in the relay division of the Tugaloo Triathlon and his team (3 Stooges) took first place in 2001, 2003 and 2005,[17] thereby serving as Georgia state champions.

Publications

[edit]

Selected papers

[edit]
  1. ^ Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray (September 2010). "Glutamate Receptor Ion Channels: Structure, Regulation, and Function". Pharmacological Reviews. 62 (3): 405–496. doi:10.1124/pr.109.002451. PMC 2964903. PMID 20716669.
  2. ^ Kleckner, Nancy W.; Dingledine, Raymond (12 August 1988). "Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes". Science. 241 (4867): 835–837. Bibcode:1988Sci...241..835K. doi:10.1126/science.2841759. PMID 2841759.
  3. ^ Traynelis, S. F.; Dingledine, R. (1 May 1989). "Role of extracellular space in hyperosmotic suppression of potassium-induced electrographic seizures". Journal of Neurophysiology. 61 (5): 927–938. doi:10.1152/jn.1989.61.5.927. PMID 2723735.
  4. ^ Traynelis, S. F.; Dingledine, R. (1 January 1988). "Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice". Journal of Neurophysiology. 59 (1): 259–276. doi:10.1152/jn.1988.59.1.259. PMID 3343603.
  5. ^ Hume, R.; Dingledine, R.; Heinemann, S. (30 August 1991). "Identification of a site in glutamate receptor subunits that controls calcium permeability". Science. 253 (5023): 1028–1031. Bibcode:1991Sci...253.1028H. doi:10.1126/science.1653450. PMID 1653450. S2CID 37111624.
  6. ^ Mott, David D.; Doherty, James J.; Zhang, Sunan; Washburn, Mark S.; Fendley, Morris J.; Lyuboslavsky, Polina; Traynelis, Stephen F.; Dingledine, Raymond (December 1998). "Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition". Nature Neuroscience. 1 (8): 659–667. doi:10.1038/3661. PMID 10196581. S2CID 2883094.
  7. ^ Vezzani, Annamaria; Friedman, Alon; Dingledine, Raymond J. (June 2013). "The role of inflammation in epileptogenesis". Neuropharmacology. 69: 16–24. doi:10.1016/j.neuropharm.2012.04.004. PMC 3447120. PMID 22521336.
  8. ^ Jiang, Jianxiong; Dingledine, Ray (July 2013). "Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection". Trends in Pharmacological Sciences. 34 (7): 413–423. doi:10.1016/j.tips.2013.05.003. PMC 4031445. PMID 23796953.
  9. ^ "Pharmacology chair elected to the Institute of Medicine". www.emory.edu. Retrieved 4 January 2023.
  10. ^ "2018 Institute of Basic Sciences - Throne Holst Symposium - Inflammation and Epilepsy – Psychology of Science". Faculty of Medicine. University of Oslo. 2018. Retrieved 4 January 2023.
  11. ^ "Emory researchers recognized for their spirit of innovation | Emory University | Atlanta GA". news.emory.edu. Retrieved 4 January 2023.
  12. ^ "2020 Fellows Bios". Default. Retrieved 4 January 2023.
  13. ^ Birmingham, Karen (1 August 2002). "Ray Dingledine". Nature Medicine. 8 (8): 772. doi:10.1038/nm0802-772. PMID 12152023. S2CID 6731617. Retrieved 27 December 2022.
  14. ^ "Raymond Dingledine awarded national pharmacology career achievement award | Emory University | Atlanta GA". news.emory.edu. Retrieved 27 December 2022.
  15. ^ "News from the Office of Development and Alumni Relations". GDBBS Alumni Newsletter. Retrieved 4 January 2023.
  16. ^ "Department of Pharmacology and Chemical Biology Establishes Ray Dingledine Award for Research Impact | Emory School of Medicine". med.emory.edu. Retrieved 4 January 2023.
  17. ^ "Active Results". resultscui.active.com. Retrieved 27 December 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Fu_Hung_Shiu/sandbox&oldid=1160945711"